Featured Research

from universities, journals, and other organizations

Drug Therapy Reduces Neuroblastoma Tumor Growth In Pre-clinical Investigation

Date:
April 30, 2009
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Researchers have discovered a new drug combination that significantly hinders tumor growth in neuroblastoma, a childhood cancer.

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered a new drug combination that significantly hinders tumor growth in neuroblastoma, a childhood cancer. The study was presented April 26 at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology (ASPHO).

By combining a novel multi-kinase inhibitor, vandetanib, with 13-cis-retinoic acid (CRA), a drug often used for severe acne, researchers from the Children's Cancer Hospital at M. D. Anderson found that the two therapies reduced neuroblastoma tumors by 86 percent in pre-clinical tests.

Peter Zage, M.D., Ph.D., who specializes in neuroblastoma at the Children's Cancer Hospital, received this year's Young Investigator Award from ASPHO and was selected to present his research today in a special platform session.

"By itself, vandetanib inhibited tumor growth by two-thirds and decreased blood vessel formation around neuroblastoma tumors in mice," says Zage. "When combined with CRA, the impact was even greater on tumor growth."

Vandetanib blocks a family of endothelial growth factors and receptors that promote tumor growth as well as the RET oncogene, which can signal neuroendocrine cells to develop into neuroblastoma cells. Although commonly used in treatment for neuroblastoma, CRA by itself does not have a significant impact against the childhood cancer. However, it works in combination therapy to differentiate neuroblastoma cells into mature benign neural cells.

Currently, there is a Phase I clinical trial open for children with multiple-relapsed neuroblastoma to further study the new therapy combination. This trial is the first in the world to test vandetanib in children.

Zage says in addition to the pediatric patients enrolled in the Phase I trial, adult patients with lung cancer have received vandetanib and have tolerated the novel drug well.

According to the American Cancer Society, approximately 650 children, mainly under the age of five, are diagnosed with neuroblastoma in the United States each year. Close to two-thirds of these children are diagnosed after the cancer has metastasized to other parts of the body. For these patients with high-risk neuroblastoma, long-term survival is less than 40 percent because the tumors are often resistant to traditional chemotherapy.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Drug Therapy Reduces Neuroblastoma Tumor Growth In Pre-clinical Investigation." ScienceDaily. ScienceDaily, 30 April 2009. <www.sciencedaily.com/releases/2009/04/090425111158.htm>.
University of Texas M. D. Anderson Cancer Center. (2009, April 30). Drug Therapy Reduces Neuroblastoma Tumor Growth In Pre-clinical Investigation. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2009/04/090425111158.htm
University of Texas M. D. Anderson Cancer Center. "Drug Therapy Reduces Neuroblastoma Tumor Growth In Pre-clinical Investigation." ScienceDaily. www.sciencedaily.com/releases/2009/04/090425111158.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com
How to Master Motherhood With the Best Work/Life Balance

How to Master Motherhood With the Best Work/Life Balance

TheStreet (Apr. 22, 2014) In the U.S., there are more than 11 million couples trying to conceive at any given time. From helping celebrity moms like Bethanny Frankel to ordinary soon-to-be-moms, TV personality and parenting expert, Rosie Pope, gives you the inside scoop on mastering motherhood. London-born entrepreneur Pope is the creative force behind Rosie Pope Maternity and MomPrep. She explains why being an entrepreneur offers the best life balance for her and tips for all types of moms. Video provided by TheStreet
Powered by NewsLook.com
Catching More Than Fish: Ugandan Town Crippled by AIDS

Catching More Than Fish: Ugandan Town Crippled by AIDS

AFP (Apr. 22, 2014) The village of Kasensero on the shores of Lake Victoria was where HIV-AIDS was first discovered in Uganda. Its transient population of fishermen and sex workers means the nationwide programme to combat the virus has had little impact. Duration: 02:30 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins